Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafterCVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review voucher, subject to a $50 million aggregate payment capSEATTLE, Sept. 29, 2026 /PRNe…